Show simple item record

dc.contributor.authorRuiz Cantero, María del Carmen 
dc.contributor.authorGonzález Cano, Rafael 
dc.contributor.authorTejada, Miguel Ángel
dc.contributor.authorSantos Caballero, Miriam 
dc.contributor.authorPerazzoli, Gloria
dc.contributor.authorNieto, Francisco
dc.contributor.authorCobos del Moral, Enrique José 
dc.date.accessioned2021-03-02T13:19:41Z
dc.date.available2021-03-02T13:19:41Z
dc.date.issued2020
dc.identifier.citationRuiz-Cantero, M. C., González-Cano, R., Tejada, M. Á., Santos-Caballero, M., Perazzoli, G., Nieto, F. R., & Cobos, E. J. (2020). Sigma-1 receptor: A drug target for the modulation of neuroimmune and neuroglial interactions during chronic pain. Pharmacological research. [DOI: 10.1016/j.phrs.2020.105339]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/66789
dc.description.abstractImmune and glial cells play a pivotal role in chronic pain. Therefore, it is possible that the pharmacological modulation of neurotransmission from an exclusively neuronal perspective may not be enough for adequate pain management, and the modulation of complex interactions between neurons and other cell types might be needed for successful pain relief. In this article, we review the current scientific evidence for the modulatory effects of sigma-1 receptors on communication between the immune and nervous systems during inflammation, as well as the influence of this receptor on peripheral and central neuroinflammation. Several experimental models of pathological pain are considered, including peripheral and central neuropathic pain, osteoarthritic, and cancer pain. Sigma-1 receptor inhibition prevents peripheral (macrophage infiltration into the dorsal root ganglion) and central (activation of microglia and astrocytes) neuroinflammation in several pain models, and enhances immune-driven peripheral opioid analgesia during painful inflammation, maximizing the analgesic potential of peripheral immune cells. Therefore, sigma-1 antagonists may constitute a new class of analgesics with an unprecedented mechanism of action and potential utility in several painful disorders.es_ES
dc.description.sponsorshipTraining University Lecturers program (FPU) of the Spanish Ministry of Economy and Competitiveness (MINECO)es_ES
dc.description.sponsorshipBiomedical Research Institute, Hospital Clfnico Universitario in Valencia (INCLIVA)es_ES
dc.description.sponsorshipSpanish State Research Agency of MINECO SAF2016-80540-R PID2019-108691RB-100es_ES
dc.description.sponsorshipAndalusian Regional Government CTS109es_ES
dc.description.sponsorshipEuropean Commissiones_ES
dc.language.isoenges_ES
dc.publisherELSEVIERes_ES
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectPain es_ES
dc.subjectEndogenous opioid analgesiaes_ES
dc.subjectNeuroinflammationes_ES
dc.subjectMacrophages es_ES
dc.subjectMicrogliaes_ES
dc.subjectAstrocytees_ES
dc.titleSigma-1 receptor: A drug target for the modulation of neuroimmune and neuroglial interactions during chronic paines_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.1016/j.phrs.2020.105339


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España